Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02923986
Recruitment Status : Withdrawn (No enrollment)
First Posted : October 5, 2016
Last Update Posted : May 28, 2020
Sponsor:
Information provided by (Responsible Party):
Bio-Path Holdings, Inc.

Tracking Information
First Submitted Date  ICMJE September 12, 2016
First Posted Date  ICMJE October 5, 2016
Last Update Posted Date May 28, 2020
Actual Study Start Date  ICMJE September 1, 2017
Actual Primary Completion Date May 27, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 12, 2019)
  • Dose Limiting Toxicity of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteria [ Time Frame: 240 days ]
    Phase 1b portion of the study: Determine the dose limiting toxicity of BP1001 in combination with Das
  • Maximum Tolerated Dose of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteria [ Time Frame: 240 days ]
    Phase 1b portion of the study: Determine the maximum tolerated dose of BP1001 in combination with Das
  • Efficacy of the combination of BP1001 and Das using hematologic response by bone marrow aspirate or biopsy and complete blood counts [ Time Frame: 240 days ]
    Phase IIa portion of the study: Assess the efficacy of the combination of BP1001 and Das
  • Efficacy of the combination of BP1001 and Das using cytogenetic response (karyotyping) by bone marrow aspirate or biopsy [ Time Frame: 240 days ]
    Phase IIa portion of the study: Assess the efficacy of the combination of BP1001 and Das
  • Efficacy of the combination of BP1001 and Das using molecular response (PCR) by bone marrow aspirate or biopsy [ Time Frame: 240 days ]
    Phase IIa portion of the study: Assess the efficacy of the combination of BP1001 and Das
Original Primary Outcome Measures  ICMJE
 (submitted: October 3, 2016)
  • Dose Limiting Toxicity of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteria [ Time Frame: 180 days ]
    Phase 1b portion of the study: Determine the dose limiting toxicity of BP1001 in combination with Das
  • Maximum Tolerated Dose of BP1001 using non-hematologic and hematologic parameters per NCI CTCAE criteria [ Time Frame: 180 days ]
    Phase 1b portion of the study: Determine the maximum tolerated dose of BP1001 in combination with Das
  • Efficacy of the combination of BP1001 and Das using hematologic response by bone marrow aspirate or biopsy and complete blood counts [ Time Frame: 180 days ]
    Phase IIa portion of the study: Assess the efficacy of the combination of BP1001 and Das
  • Efficacy of the combination of BP1001 and Das using cytogenetic response (karyotyping) by bone marrow aspirate or biopsy [ Time Frame: 180 days ]
    Phase IIa portion of the study: Assess the efficacy of the combination of BP1001 and Das
  • Efficacy of the combination of BP1001 and Das using molecular response (PCR) by bone marrow aspirate or biopsy [ Time Frame: 180 days ]
    Phase IIa portion of the study: Assess the efficacy of the combination of BP1001 and Das
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 12, 2019)
  • Safety of BP1001 in combination with Das using non-hematologic and hematologic parameters per NCI CTCAE criteria [ Time Frame: 30 days ]
    Evaluate Safety of BP1001 in combination with Das
  • Efficacy of the combination of BP1001 and Das using hematologic response by bone marrow aspirate or biopsy and complete blood counts versus Das alone by historical outcome comparison [ Time Frame: 240 days ]
    Determine whether the combination of BP1001 and Das provides greater efficacy (Hematologic Response) than Das alone (by historical comparison)
  • Efficacy of the combination of BP1001 and Das using cytogenetic response (karyotyping) by bone marrow aspirate or biopsy versus Das alone by historical outcome comparison [ Time Frame: 240 days ]
    Determine whether the combination of BP1001 and Das provides greater efficacy (Cytogenetic Response) than Das alone (by historical comparison)
  • Efficacy of the combination of BP1001 and Das using molecular response (PCR) by bone marrow aspirate or biopsy versus Das alone by historical outcome comparison [ Time Frame: 240 days ]
    Determine whether the combination of BP1001 and Das provides greater efficacy (Molecular Response) than Das alone (by historical comparison)
  • In vivo PK using plasma to compute half life and elimination [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001 when given alone and in combination with Das
  • Time to Response using hematologic response using bone marrow biopsy or aspirate and complete blood counts [ Time Frame: 30 days ]
    Assess time to response from administration of BP1001 + Das to hematologic response
  • Time to Response using cytogenetic response (karyotyping) using bone marrow biopsy or aspirate [ Time Frame: 30 days ]
    Assess time to response from administration of BP1001 + Das to cytogenetic response
  • Time to Response using molecular response (PCR) using bone marrow biopsy or aspirate [ Time Frame: 30 days ]
    Assess time to response from administration of BP1001 + Das to molecular response
  • Duration of Response using hematologic response using bone marrow biopsy or aspirate and complete blood counts from day of response to day of disease progression [ Time Frame: 30 days ]
    Assess duration of response from day of response to day of disease progression
  • Duration of Response using cytogenetic response (karyotyping) using bone marrow biopsy or aspirate from day of response to day of disease progression [ Time Frame: 30 days ]
    Assess duration of response from day of response to day of disease progression
  • Duration of Response using molecular response (PCR) using bone marrow biopsy or aspirate from day of response to day of disease progression [ Time Frame: 30 days ]
    Assess duration of response from day of response to day of disease progression
  • Overall Survival from date of study entry to study closure [ Time Frame: 240 days ]
    Assess overall survival from date of study entry to study closure
Original Secondary Outcome Measures  ICMJE
 (submitted: October 3, 2016)
  • Safety of BP1001 in combination with Das using non-hematologic and hematologic parameters per NCI CTCAE criteria [ Time Frame: 30 days ]
    Evaluate Safety of BP1001 in combination with Das
  • Efficacy of the combination of BP1001 and Das using hematologic response by bone marrow aspirate or biopsy and complete blood counts versus Das alone by historical outcome comparison [ Time Frame: 180 days ]
    Determine whether the combination of BP1001 and Das provides greater efficacy (Hematologic Response) than Das alone (by historical comparison)
  • Efficacy of the combination of BP1001 and Das using cytogenetic response (karyotyping) by bone marrow aspirate or biopsy versus Das alone by historical outcome comparison [ Time Frame: 180 days ]
    Determine whether the combination of BP1001 and Das provides greater efficacy (Cytogenetic Response) than Das alone (by historical comparison)
  • Efficacy of the combination of BP1001 and Das using molecular response (PCR) by bone marrow aspirate or biopsy versus Das alone by historical outcome comparison [ Time Frame: 180 days ]
    Determine whether the combination of BP1001 and Das provides greater efficacy (Molecular Response) than Das alone (by historical comparison)
  • In vivo PK using plasma to compute half life and elimination [ Time Frame: 30 days ]
    Evaluate in vivo PK of BP1001 when given alone and in combination with Das
  • Time to Response using hematologic response using bone marrow biopsy or aspirate and complete blood counts [ Time Frame: 30 days ]
    Assess time to response from administration of BP1001 + Das to hematologic response
  • Time to Response using cytogenetic response (karyotyping) using bone marrow biopsy or aspirate [ Time Frame: 30 days ]
    Assess time to response from administration of BP1001 + Das to cytogenetic response
  • Time to Response using molecular response (PCR) using bone marrow biopsy or aspirate [ Time Frame: 30 days ]
    Assess time to response from administration of BP1001 + Das to molecular response
  • Duration of Response using hematologic response using bone marrow biopsy or aspirate and complete blood counts from day of response to day of disease progression [ Time Frame: 30 days ]
    Assess duration of response from day of response to day of disease progression
  • Duration of Response using cytogenetic response (karyotyping) using bone marrow biopsy or aspirate from day of response to day of disease progression [ Time Frame: 30 days ]
    Assess duration of response from day of response to day of disease progression
  • Duration of Response using molecular response (PCR) using bone marrow biopsy or aspirate from day of response to day of disease progression [ Time Frame: 30 days ]
    Assess duration of response from day of response to day of disease progression
  • Overall Survival from date of study entry to study closure [ Time Frame: 180 days ]
    Assess overall survival from date of study entry to study closure
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Official Title  ICMJE A Phase Ib/IIa Single-arm, Open-label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Including Chronic Phase Patients Who Have Failed Initial Tyrosine Kinase Inhibitor (TKI) Therapy, Accelerated or Blast Phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS)
Brief Summary The primary objective of the Phase Ib study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 in combination with dasatinib in patients with with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) including chronic phase patients who have failed initial tyrosine kinase inhibitor (TKI) therapy, accelerated or blast phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS). The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and dasatinib in patients with Ph+ CML, Ph+AML, or high-risk Ph+ MDS.
Detailed Description

The Grb2 gene has been mapped to the human chromosome region 17q22-qter, a region that is duplicated in leukemias and solid tumors, which may result in an increased copy number of the Grb2 gene product. As Grb2 is important for the transformation of murine hematopoietic cells, and the proliferation of human leukemia cells that express high levels of oncogenic tyrosine kinases, inhibition of Grb2 may have a significant impact on the natural history of leukemias. The study drug (BP1001) may be able to inhibit the cells from making Grb-2. Researchers hope that without this protein, the leukemia cells will die.

Researchers hope that the combination of BP1001 and Das will provide a benefit to Ph+ CML patients, including chronic phase patients who have failed initial TKI therapy, accelerated or blast phase Ph+ AML, and high-risk Ph+ MDS patients.

This is a Phase Ib/IIa, multicenter, study of BP1001 in combination with Das in participants with Ph+ CML, including chronic phase patients who have failed initial TKI therapy, accelerated or blast phase Ph+ AML, and high-risk Ph+ MDS.

This is a Phase Ib/IIa, multicenter, study of BP1001 in combination with dasatinib in participants with Ph+ CML who are in chronic phase who have failed initial TKI therapy, accelerated or blast phase, Ph+ AML or high-risk Ph+ MDS.

This trial will utilize a single arm, open label design to assess the safety profile, DLT, MTD, PK, and efficacy of BP1001 in combination with dasatinib.

The Phase Ib study employs an open-label, sequential, dose-escalation design to assess safety, tolerability and toxicity, tumor response and anti-leukemic activity.

A standard "3+3" design will be used in which successive cohorts of patients are being treated with BP1001 at the MTD (or highest tested dose [HTD] if the MTD is not defined) and 1 level below the MTD (or HTD) in combination with a fixed dose of dasatinib to characterize safety and biological effect, as well as identify the recommended Phase IIa dose.

Up to 6 evaluable participants are expected to participate in the Phase Ib part of the study and up to 40 evaluable participants are expected to participate in the Phase IIa part of the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Chronic Myelogenous Leukemia, Ph1-Positive
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
Intervention  ICMJE
  • Drug: BP1001 (varying dose)
    BP1001 (varying dose)
    Other Names:
    • Liposomal Grb-2
    • L-Grb-2
  • Drug: BP1001 (fixed dose)
    BP1001 (fixed dose)
    Other Names:
    • Liposomal Grb-2
    • L-Grb-2
  • Drug: Dasatinib
    Dasatinib
    Other Name: Das
Study Arms  ICMJE
  • Experimental: BP1001 (varying dose) + Dasatinib
    Phase 1b: BP1001 (varying dose levels) in combination with Das
    Interventions:
    • Drug: BP1001 (varying dose)
    • Drug: Dasatinib
  • Experimental: BP1001 (fixed dose) + Dasatinib
    Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
    Interventions:
    • Drug: BP1001 (fixed dose)
    • Drug: Dasatinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: May 26, 2020)
0
Original Estimated Enrollment  ICMJE
 (submitted: October 3, 2016)
46
Actual Study Completion Date  ICMJE May 27, 2020
Actual Primary Completion Date May 27, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

At the time of Screening, participants must meet all of the following criteria to be considered eligible to participate in the study:

  1. Adults ≥18 years of age
  2. Females must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study and for 30 days after the last dose of study drug or dasatinib
  3. Males must agree to use an adequate method of contraception during the study and for at least 30 days after the last dose of study drug or dasatinib
  4. Histologically documented diagnosis of Ph+ CML including chronic phase patients who have failed initial TKI therapy, accelerated or blast phase, Ph+ AML or High-risk Ph+ MDS.

    Ph+ chronic phase CML patients who are resistant to 1 or more TKIs, including dasatinib. Dasatinib-resistant patients can enroll in the Phase Ib portion of the study but are excluded from the Phase IIa portion of the study.

    One of the following parameters is required to meet criteria for accelerated CML:

    • Blasts in Peripheral Blood or Bone Marrow ≥15%
    • Promyelocytes and Blasts in Peripheral Blood or Bone Marrow ≥30%
    • PB or BM basophils ≥20%
    • Thrombocytopenia <100 x 103/ml, not resulting from therapy
    • Cytogenetic clonal evolution CML blast phase is defined as ≥30% blasts in peripheral blood or bone marrow, or presence of extramedullary disease, except for liver or spleen.

    AML/MDS

    Ph+ AML is defined as:

    • Ph+ and meets diagnostic criteria for AML

    o Myeloid blasts ≥20 % or presence of AML-defining recurrent cytogenetic abnormality.

    Ph+ high-risk MDS defined as:

    • Ph+ high risk MDS ≥10% myeloid blasts or IPSS ≥intermediate-2

  5. Adequate hepatic and renal functions as defined by:

    1. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN); and
    2. Total bilirubin ≤1.5 times ULN; and
    3. Estimated glomerular filtration rate (eGFR) of at least 40 ml/min. These estimations can be calculated using any of the following methods (Appendix D):

    i. Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation

    • GFR = 141 × min (Scr /κ, 1)α × max(Scr /κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black] ii. Cockcroft gault equation
    • Cockcroft Gault equation utilizing the TBW (Total body weight) to calculate an estimated creatinine clearance iii. CrCl = [(140 - age) x TBW] / (Scr x 72) x 0.85 [if female]
    • Modification of Diet in Renal Disease (MDRD) Study equation iv. GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × 0.74 [if female] x 1.212 [if African American (AA)]
    • Creatinine clearance estimated by 24-hr urine collection for creatinine clearance
  6. Documented Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  7. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
  8. Willing and able to provide written informed consent

Exclusion Criteria

At the time of Screening, participants who meet any of the following criteria will be excluded from participating in the study:

  1. Patients with T315I mutation will not be excluded, but their response will be analyzed separately.
  2. Another primary malignancy other than CML, AML, or MDS within the past 2 years except non-melanoma skin cancer, or carcinoma in situ of the cervix.
  3. Known, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Patients with a history of CNS disease may be allowed to participate based on at least 2 consecutive documented, negative spinal fluid assessment prior to Screening
  4. Isolated extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (i.e., ≥20% blasts in bone marrow aspirate)
  5. Receipt of any anti-cancer therapy within 14 days of starting BP1001, with the exception of hydroxyurea or anagrelide, or TKI (within 2 days)
  6. Uncontrolled active, untreated, or progressive infection
  7. Receipt of any investigational agent within 14 days or 5 half-lives of starting BP1001
  8. Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
  9. Prior exposure to BP1001
  10. Patients with a history of intolerance to dasatinib or for whom dasatinib may not be appropriate
  11. Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study
  12. Known active or clinically significant hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on positive antibody [HCV Ab]), or human immunodeficiency virus (HIV-1 or HIV-2, based on positive antibody)
  13. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant ECG abnormality (e.g., QTcF >470 msec)
  14. Has had any of the following: clinically significant pleural effusion within 2 months, myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack within 6 months.
  15. Uncontrolled seizure disorder (i.e., seizures within the past 2 months).
  16. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02923986
Other Study ID Numbers  ICMJE BP1001-202-CML
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Bio-Path Holdings, Inc.
Study Sponsor  ICMJE Bio-Path Holdings, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Maro Ohanian, M.D. M.D. Anderson Cancer Center
PRS Account Bio-Path Holdings, Inc.
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP